Raltitrexed (Tomudex):: an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity

被引：62
|
作者：
Köhne, CH
Thuss-Patience, P
Friedrich, M
Daniel, PT
Kretzschmar, A
Benter, T
Bauer, B
Dietz, R
Dörken, B
机构：
[1] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Robert Rossle Klin, Dept Haematol Oncol & Tumor Immunol, D-13125 Berlin, Germany
[2] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Franz Volhard Klin, Dept Clin & Mol Cardiol, D-13125 Berlin, Germany
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 77卷 / 06期
关键词：
5-fluorouracil; cardiotoxicity; raltitrexed; colorectal neoplasms;
D O I：
10.1038/bjc.1998.160
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.
引用
收藏
页码：973 / 977
页数：5
相关论文
共 50 条
  • [21] Symptomatic cardiotoxicity associated with 5-fluorouracil
    Meyer, CC
    Calis, KA
    Burke, LB
    Walawander, CA
    Grasela, TH
    PHARMACOTHERAPY, 1997, 17 (04): : 729 - 736
  • [22] Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia cancer agency experience
    Wilson, Kenneth S.
    Fitzgerald, Catherine A.
    Barnett, Jeff B.
    Gill, Sharlene
    Khoo, Kong E.
    CANCER INVESTIGATION, 2007, 25 (08) : 711 - 714
  • [23] Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer
    Schwartz, GK
    Bertino, J
    Kemeny, N
    Saltz, L
    Kelsen, DK
    Tong, W
    Welch, M
    Endres, S
    Dimery, I
    ANTI-CANCER DRUGS, 2004, 15 (03) : 219 - 227
  • [24] Cardiotoxicity in 5-fluorouracil folinic acid treatment for metastatic colorectal cancer
    Käfer, G
    Achtnich, M
    Willer, A
    Weiss, A
    Queisser, W
    ONKOLOGIE, 1998, 21 (04): : 324 - 327
  • [25] Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure
    Decoster, L
    Neyns, B
    Akouaouach, H
    Fontaine, C
    Schallier, D
    De Gréve, JLP
    ANTICANCER RESEARCH, 2004, 24 (3B) : 2037 - 2040
  • [26] Adjuvant therapy (AT) with raltitrexed (RAL) in colorectal cancer (CRC) patients (pts) intolerant of 5-fluorouracil (5FU).
    Wilson, K. S.
    Barnett, J. B.
    Gill, S.
    Khoo, K. E.
    Fitzgerald, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [27] Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer
    Kerr, DJ
    ANTI-CANCER DRUGS, 1997, 8 : S11 - S15
  • [28] Bolus 5-Fluorouracil as an Alternative Modality to Infusion 5-Fluorouracil in a Patient with Rectal Cancer and Capecitabine-induced Cardiotoxicity
    Shaib, Walid
    Lee, Veronica
    Saif, M. Wasif
    IN VIVO, 2009, 23 (05): : 821 - 826
  • [29] CARDIOTOXICITY OF 5-FLUOROURACIL
    MAY, D
    WANDL, U
    BECHER, R
    NIEDERLE, N
    SCHMIDT, CG
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1990, 115 (16) : 618 - 621
  • [30] CARDIOTOXICITY OF 5-FLUOROURACIL
    GAMUCCI, T
    ZAMPA, G
    TUMORI, 1980, 66 (05) : 635 - 636
12345